<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335136</url>
  </required_header>
  <id_info>
    <org_study_id>APN01-01-COVID19</org_study_id>
    <nct_id>NCT04335136</nct_id>
  </id_info>
  <brief_title>Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19</brief_title>
  <acronym>APN01-COVID-19</acronym>
  <official_title>Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apeiron Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apeiron Biologics</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recombinant human angotensin-converting enzyme 2 (rhACE2) as a treatment for patients with
      COVID-19 to block viral entry and decrease viral replication.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All Cause-death or invasive mechanical ventilation</measure>
    <time_frame>28 days</time_frame>
    <description>The primary endpoint is a composite endpoint of all cause-death or invasive mechanical ventilation up to 28 days or hospital discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LDH level</measure>
    <time_frame>Day 5</time_frame>
    <description>Log transformed levels of Lactate dehydrogenase (LDH) at day 5 as a surrogate marker for organ damage (powered secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>28-day mortality (all cause-death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VFD</measure>
    <time_frame>28 days</time_frame>
    <description>Ventilator-free days (VFD) up to 28 days or hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>28 days</time_frame>
    <description>Time to death (all causes)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Group A (active) APN01</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recombinant human angiotensin-converting enzyme 2 (rhACE2) - APN01</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (placebo control)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RhACE2 APN01</intervention_name>
    <description>Patients will be treated with APN01 intravenously twice daily (BID).</description>
    <arm_group_label>Group A (active) APN01</arm_group_label>
    <other_name>APN01</other_name>
    <other_name>Recombinant human angiotensin-converting enzyme 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physiological saline solution</intervention_name>
    <description>Patients will be treated with placebo intravenously twice daily (BID).</description>
    <arm_group_label>Group B (placebo control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hospitalized male or female

          2. Diagnosed to be COVID-19 POSITIV

          3. Signed Inform Consent Form

        Exclusion Criteria:

          1. Any patient whose clinical condition is deteriorating rapidly

          2. Known history of positive Hepatitis B surface antigen, Hepatitis C antibody or HIV
             antibody

          3. History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the investigator or Medical
             Monitor, contraindicates their participation

          4. Pregnant females as determined by positive serum or urine hCG test prior to dosing

          5. Lung transplantation

          6. Pre-existing renal failure, i.e. requiring renal replacement therapy with hemodialysis
             or peritoneal dialysis

          7. There are other uncontrolled co-morbidities that increase the risks associated with
             the study drug administration, that are assessed by the medical expert team as
             unsuitable

          8. Patient in clinical trials for COVID-19 within 30 days before ICF

          9. Immunocompromised patients (chemotherapy, HIV, organ transplants, stem cell
             transplants)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Bundgaard, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Capital Region's Unit of Inherited Cardiac Diseases Faculty of Health and Medical Sciences University of Copenhagen Rigshospitalet, University of Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sonja Höller, Dr.</last_name>
    <phone>43 1 865 65 77 128</phone>
    <email>sonja.hoeller@apeiron-biologics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Günter Weiss, Univ.-Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Franz Josef Spital, 4. Medizinische Abteilung mit Infektions- und Tropenmedizin</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Zoufaly, Priv.-Doz. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Ullrich, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The National University Hospital, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Gerstoft, Prof. Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev Gentofte Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Søborg</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nordsjællands Hospital</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Troels B. Knudsen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas L. Benfield, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Schmiedel, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, Technische Universität München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph D. Spinner, PD DR. med.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

